Pembrolizumab (pembro) for patients (pts) with high-risk non-muscle-invasive bladder cancer (hr nmibc) unresponsive to bacillus calmette-guerin (bcg): efficacy and evaluation of subsequent cystectomy from cohort b of the phase 2 keynote-057 study